

Shaoying Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5677393/publications.pdf>

Version: 2024-02-01

74
papers

3,016
citations

185998

28
h-index

168136

53
g-index

75
all docs

75
docs citations

75
times ranked

3345
citing authors

#	ARTICLE	IF	CITATIONS
1	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. <i>Modern Pathology</i> , 2022, 35, 419-426.	2.9	16
2	Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2022, 35, 412-418.	2.9	4
3	Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall. <i>Human Pathology</i> , 2022, 119, 59-68.	1.1	2
4	Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation. <i>Human Pathology</i> , 2022, 121, 36-45.	1.1	11
5	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (≥ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2022, 23, 406-415.	5.1	22
6	Richter transformation with marked plasmacytic differentiation, mimicking plasma cell neoplasm. <i>EJHaem</i> , 2022, 3, 241-242.	0.4	0
7	Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. <i>Pathology</i> , 2022, . .	0.3	0
8	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. <i>Biomedicines</i> , 2022, 10, 1587.	1.4	6
9	MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. <i>Haematologica</i> , 2021, 106, 1381-1389.	1.7	25
10	$SOX11$, MME, $TP53$ mutated high-grade pleomorphic mantle cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 165-166.	2.0	2
11	Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. <i>British Journal of Haematology</i> , 2021, 192, e17-e21.	1.2	2
12	MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. <i>Human Pathology</i> , 2021, 108, 22-31.	1.1	6
13	Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. <i>Modern Pathology</i> , 2021, 34, 300-313.	2.9	6
14	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. <i>Modern Pathology</i> , 2021, 34, 327-335.	2.9	7
15	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	2.0	6
16	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. <i>Modern Pathology</i> , 2021, 34, 2183-2191.	2.9	7
17	The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
18	Blast phase of chronic myeloid leukemia presenting as early T-cell precursor lymphoblastic leukemia. <i>EJHaem</i> , 2021, 2, 895.	0.4	0

#	ARTICLE	IF	CITATIONS
19	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. <i>Cancers</i> , 2021, 13, 6316.	1.7	1
20	The pathologic diagnosis of mantle cell lymphoma. <i>Histology and Histopathology</i> , 2021, , 18351.	0.5	2
21	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. <i>Modern Pathology</i> , 2020, 33, 324-333.	2.9	31
22	Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. <i>Modern Pathology</i> , 2020, 33, 1104-1121.	2.9	19
23	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 372-381.	1.2	51
24	Reply to "PD-L1 expression in anaplastic large cell lymphoma". <i>Modern Pathology</i> , 2020, 33, 1234-1235.	2.9	0
25	iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. <i>Modern Pathology</i> , 2020, 33, 1389-1397.	2.9	8
26	<i>MYC</i> rearrangement and <i>MYC/BCL2</i> double expression but not cell of origin predict prognosis in R-CHOP-treated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 336-343.	1.1	15
27	CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. <i>Human Pathology</i> , 2020, 98, 1-9.	1.1	9
28	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) -outcomes and mutation profile from venetoclax resistant MCL patients. <i>American Journal of Hematology</i> , 2020, 95, 623-629.	2.0	54
29	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
30	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. <i>Blood Advances</i> , 2020, 4, 1038-1050.	2.5	43
31	Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 376-385.	1.2	4
32	CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. <i>Human Pathology</i> , 2019, 89, 71-80.	1.1	23
33	Relapsed acute lymphoblastic leukemia with aberrant myeloperoxidase expression following CAR T-cell therapy: A diagnostic challenge. <i>American Journal of Hematology</i> , 2019, 94, 1049-1051.	2.0	11
34	CD138 ⁺ plasma cell myeloma. <i>Blood</i> , 2019, 134, 906-906.	0.6	4
35	SOX11-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 710-716.	2.1	22
36	CD5-negative Mantle Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1052-1060.	2.1	25

#	ARTICLE	IF	CITATIONS
37	Focal Rosaiâ€Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. <i>Modern Pathology</i> , 2019, 32, 16-26.	2.9	32
38	Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 304-316.	0.6	11
39	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. <i>Modern Pathology</i> , 2018, 31, 327-336.	2.9	46
40	Diffuse large B-cell lymphoma. <i>Pathology</i> , 2018, 50, 74-87.	0.3	395
41	Extensive Kaposi sarcoma infiltration in bone marrow in a patient with HIV. <i>Blood</i> , 2018, 132, 2525-2525.	0.6	2
42	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. <i>British Journal of Haematology</i> , 2018, 183, 578-587.	1.2	81
43	MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. <i>Modern Pathology</i> , 2018, 31, 1470-1478.	2.9	50
44	Advances in pathological understanding of high-grade B cell lymphomas. <i>Expert Review of Hematology</i> , 2018, 11, 637-648.	1.0	20
45	Myelodysplastic Syndrome. <i>Molecular Pathology Library</i> , 2018, , 83-98.	0.1	1
46	CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. <i>Oncotarget</i> , 2018, 9, 11441-11450.	0.8	27
47	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. <i>Modern Pathology</i> , 2017, 30, 734-744.	2.9	28
48	Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not <i>MLL</i> gene. <i>Journal of Clinical Pathology</i> , 2017, 70, 244-249.	1.0	7
49	Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. <i>Blood</i> , 2017, 129, 2593-2593.	0.6	5
50	Mantle Cell Lymphoma With MYC Rearrangement. <i>American Journal of Surgical Pathology</i> , 2017, 41, 216-224.	2.1	48
51	Prognostic impact of <i>CD</i> 5 expression in diffuse large B-cell lymphoma in patients treated with rituximabâ€EPOCH. <i>European Journal of Haematology</i> , 2017, 98, 415-421.	1.1	41
52	Distinguishing Between Hepatosplenic T-cell Lymphoma and T-cell Large Granular Lymphocytic Leukemia. <i>American Journal of Surgical Pathology</i> , 2017, 41, 82-93.	2.1	42
53	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 1688-1697.	2.9	46
54	Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosaiâ€Dorfman disease. <i>Modern Pathology</i> , 2017, 30, 1367-1377.	2.9	186

#	ARTICLE	IF	CITATIONS
55	CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2017, 60, 160-166.	1.1	11
56	P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2017, 30, 194-203.	2.9	72
57	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	0.8	132
58	<i>MYC/BCL6</i> double-hit lymphoma (<i>DHL</i>): a tumour associated with an aggressive clinical course and poor prognosis. <i>Histopathology</i> , 2016, 68, 1090-1098.	1.6	81
59	Prognostic Factors of Hepatosplenic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 676-688.	2.1	65
60	<i>CD30</i> expression and its correlation with <i>MYC</i> rearrangement in <i>de novo</i> diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 39-47.	1.1	16
61	Double-hit follicular lymphoma with <i>MYC</i> and <i>BCL2</i> translocations: a study of 7 cases with a review of literature. <i>Human Pathology</i> , 2016, 58, 72-77.	1.1	33
62	High-grade B-cell Lymphoma With <i>MYC</i> Rearrangement and Without <i>BCL2</i> and <i>BCL6</i> Rearrangements Is Associated With High P53 Expression and a Poor Prognosis. <i>American Journal of Surgical Pathology</i> , 2016, 40, 253-261.	2.1	51
63	<i>miR-31</i> and <i>miR-17-5p</i> levels change during transformation of follicular lymphoma. <i>Human Pathology</i> , 2016, 50, 118-126.	1.1	23
64	<i>BRAF</i> and <i>MAP2K1</i> mutations in Langerhans cell histiocytosis: a study of 50 cases. <i>Human Pathology</i> , 2016, 52, 61-67.	1.1	70
65	The clinical significance of <i>8q24/MYC</i> rearrangement in chronic lymphocytic leukemia. <i>Modern Pathology</i> , 2016, 29, 444-451.	2.9	18
66	Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with <i>MYC/BCL2</i> double hit lymphoma. <i>Oncotarget</i> , 2016, 7, 38122-38132.	0.8	30
67	<i>MYC</i> Cytogenetic Status Correlates With Expression and Has Prognostic Significance in Patients With <i>MYC/BCL2</i> Protein Double-positive Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1250-1258.	2.1	51
68	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 74.	6.9	15
69	B-cell lymphomas with concurrent <i>MYC</i> and <i>BCL2</i> abnormalities other than translocations behave similarly to <i>MYC/BCL2</i> double-hit lymphomas. <i>Modern Pathology</i> , 2015, 28, 208-217.	2.9	75
70	Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 32.	6.9	30
71	Clinical significance of newly emerged isolated <i>del(20q)</i> in patients following cytotoxic therapies. <i>Modern Pathology</i> , 2015, 28, 1014-1022.	2.9	20
72	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382

#	ARTICLE	IF	CITATIONS
73	MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 315-326.	2.4	72
74	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. <i>Modern Pathology</i> , 2012, 25, 145-156.	2.9	224